MX2016002823A - Metodos y composiciones para vacunas vectorizadas virales. - Google Patents

Metodos y composiciones para vacunas vectorizadas virales.

Info

Publication number
MX2016002823A
MX2016002823A MX2016002823A MX2016002823A MX2016002823A MX 2016002823 A MX2016002823 A MX 2016002823A MX 2016002823 A MX2016002823 A MX 2016002823A MX 2016002823 A MX2016002823 A MX 2016002823A MX 2016002823 A MX2016002823 A MX 2016002823A
Authority
MX
Mexico
Prior art keywords
methods
compositions
vaccine
vector
vectored vaccines
Prior art date
Application number
MX2016002823A
Other languages
English (en)
Inventor
Chu Tang De-
Original Assignee
Altimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altimmune Inc filed Critical Altimmune Inc
Publication of MX2016002823A publication Critical patent/MX2016002823A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)

Abstract

Se proporcionan en la presente métodos y composiciones para administración no invasiva de una vacuna de vector adenoviral (vector Ad) con un adyuvante, como agonista de TLR3. Estos métodos proporcionan, por ejemplo, un incremento en la respuesta inmunológica a la vacuna, un incremento en la inmunogenicidad de la vacuna de vector Ad, un efecto de ahorro de antígeno y seguridad mejorada con una respuesta inmunológica protectora efectiva a la vacuna.
MX2016002823A 2013-09-06 2014-09-05 Metodos y composiciones para vacunas vectorizadas virales. MX2016002823A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361874505P 2013-09-06 2013-09-06
PCT/US2014/054234 WO2015035128A1 (en) 2013-09-06 2014-09-05 Methods and compositions for viral vectored vaccines

Publications (1)

Publication Number Publication Date
MX2016002823A true MX2016002823A (es) 2016-12-16

Family

ID=52625855

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002823A MX2016002823A (es) 2013-09-06 2014-09-05 Metodos y composiciones para vacunas vectorizadas virales.

Country Status (8)

Country Link
US (1) US20150071964A1 (es)
EP (1) EP3041503A4 (es)
JP (1) JP2016529316A (es)
KR (1) KR20160049010A (es)
AU (1) AU2014315124A1 (es)
CA (1) CA2923406A1 (es)
MX (1) MX2016002823A (es)
WO (1) WO2015035128A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10183069B2 (en) 2011-03-21 2019-01-22 Altimmune Inc. Rapid and prolonged immunologic-therapeutic
WO2018071233A1 (en) 2016-10-12 2018-04-19 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
EP3953457A4 (en) * 2019-04-06 2023-01-11 Altimmune Inc BROAD AND LONG-TERM FLU VACCINE
TW202308629A (zh) 2021-04-28 2023-03-01 法商Ｅｎｙｏ製藥公司 使用fxr激動劑作為組合治療以增強tlr3激動劑之療效

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2712673C2 (de) * 1977-03-23 1983-12-15 Krauss U. Reichert Gmbh + Co Kg Spezialmaschinenfabrik, 7012 Fellbach Stoßmessermaschine
US20030134815A1 (en) * 1991-08-20 2003-07-17 The Govt. Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services Adenovirus mediated transfer of genes to the gastrointestinal tract
ATE535231T1 (de) * 2002-07-03 2011-12-15 Oncovir Inc Verfahren zur herstellung von poly-iclc und seine verwendung
US8592391B2 (en) * 2003-07-01 2013-11-26 Andres Salazar Method for therapeutic, clinical and veterinary use poly-ICLC
WO2005013898A2 (en) * 2003-07-11 2005-02-17 Vaxin, Inc. Novel targets and compositions for use in decontamination, immunoprophylaxis, and post-exposure therapy against anthrax
US7834064B2 (en) * 2005-01-03 2010-11-16 Andres Mario Salazar Clinical method for the immunomodulatory and vaccine adjuvant use of poly-ICLC and other dsRNAs
EP1899470A4 (en) * 2005-05-23 2009-07-29 Vaxin Inc SYSTEM FOR THE FAST MANUFACTURE OF REPLICATED COMPETENCE OF ADENOVIRUS-FREE RECOMBINANT ADENOVIRUS VECTORS WITH HIGH TITER
JP2009512421A (ja) * 2005-08-15 2009-03-26 ヴァクシン インコーポレイテッド 非複製性ベクターワクチン投与による鳥類への免疫方法
MY154956A (en) * 2006-02-28 2015-08-28 Vaxart Inc Chimeric adenoviral vectors
WO2009146523A1 (en) * 2008-06-05 2009-12-10 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
KR20110081222A (ko) * 2008-09-26 2011-07-13 어번 유니버시티 비복제성 벡터화된 백신의 점막 투여에 의한 조류의 면역화
US9603919B2 (en) * 2009-03-31 2017-03-28 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Method for prophylaxis of influenza using vaccine for intranasal administration
BRPI1012951A2 (pt) * 2009-06-09 2016-07-26 Defyrus Inc "administração de interferon para profilaxia ou tratamento de infecção por patôgeno"
WO2012129295A1 (en) * 2011-03-21 2012-09-27 Vaxin Inc. Rapid and prolonged immunologic-therapeutic

Also Published As

Publication number Publication date
EP3041503A4 (en) 2017-06-07
AU2014315124A1 (en) 2016-04-07
JP2016529316A (ja) 2016-09-23
EP3041503A1 (en) 2016-07-13
US20150071964A1 (en) 2015-03-12
WO2015035128A1 (en) 2015-03-12
KR20160049010A (ko) 2016-05-04
CA2923406A1 (en) 2015-03-12

Similar Documents

Publication Publication Date Title
PH12018500127A1 (en) Vaccine compositions
AR118725A2 (es) Vectores para expresión de antígenos asociados a próstata
MX2023000211A (es) Composiciones de vacuna que tienen estabilidad e inmunogenicidad mejoradas.
MX2018007627A (es) Vacuna contra el virus del zika.
MX342716B (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
WO2013106834A3 (en) Immunogenic wt-1 peptides and methods of use thereof
MX2017004897A (es) Cepas vacunales recombinantes de listeria y metodos para usar las mismas en la inmunoterapia contra el cancer.
AU2015296298A8 (en) Flagellin-based agents and uses including effective vaccination
WO2015142671A3 (en) Influenza virus vectors and uses therefor
MX2015008847A (es) Composiciones inmunogenicas de virus de influenza y usos de las mismas.
MX2018004598A (es) Cepas vacunales recombinantes de listeria y métodos para usar las mismas en la inmunoterapia contra el cáncer.
WO2013054199A3 (en) Cmv antigens and uses thereof
PH12015501716B1 (en) Anti-mycoplasma spp. subunit vaccine
CL2017002971A1 (es) Composiciones y métodos para aumentar la respuesta inmune contra patógenos entéricos (solicitud divisional 2741-2015)
MX2014010417A (es) Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo.
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
PH12018502403A1 (en) Hiv vaccine formulation
NZ715459A (en) A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same
MY202024A (en) Novel mucosal adjuvants and delivery systems
NZ630831A (en) Compositions and methods for administration of vaccines against dengue virus
CO6561819A2 (es) Vectores para vacunas y método para potenciar respuestas inmunes
CL2018000609A1 (es) Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue.
MX2022013912A (es) Procedimientos novedosos para inducir una respuesta inmunitaria.
AR090450A1 (es) Vacuna de herpesvirus-1 equino recombinante que contiene glicoproteina c mutada y usos de la misma